Press release
B-Cell Non-Hodgkin Lymphoma Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Biegene, Oncternal Therapeutics, ZAI Lab, Pfizer, Xynomic Pharma, SystImmune Inc., Autolus Limited, Vincerx Pharma, U
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, B-Cell Non-Hodgkin Lymphoma pipeline constitutes 75+ key companies continuously working towards developing 80+ B-Cell Non-Hodgkin Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight."B-Cell Non-Hodgkin Lymphoma Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the B-Cell Non-Hodgkin Lymphoma Market.
The B-Cell Non-Hodgkin Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the B-Cell Non-Hodgkin Lymphoma Pipeline Report: https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel B-Cell Non-Hodgkin Lymphoma treatment therapies with a considerable amount of success over the years.
• B-Cell Non-Hodgkin Lymphoma companies working in the treatment market are Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Autolus Limited, SystImmune Inc, Hanmi Pharmaceutical, Xynomic Pharmaceuticals, Pfizer, ZAI Lab, Oncternal Therapeutics, Pfizer, Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics, Inc., and others, are developing therapies for the B-Cell Non-Hodgkin Lymphoma treatment
• Emerging B-Cell Non-Hodgkin Lymphoma therapies in the different phases of clinical trials are- VIP 924, UBX-303-1, BMF-219, SHR-A1912, Ociperlimab, AUTO3, GNC-038, Poseltinib, Abexinostat, PF-07901801, Odronextamab, Zilovertamab, PF-07901801, LP-168, TG-1801, and others are expected to have a significant impact on the B-Cell Non-Hodgkin Lymphoma market in the coming years.
• In February 2025, Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has announced the launch of waveLINE-010, a pivotal Phase 3 clinical trial. The study is evaluating the combination of zilovertamab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) versus the standard regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Zilovertamab vedotin is Merck's investigational antibody-drug conjugate targeting ROR1. Global patient enrollment for the trial is now underway.
• In January 2025, Australian immuno-oncology company Imugene administered the first dose to an Australian participant in its Phase Ib clinical trial of azer-cel (azercabtagene zapreleucel), an allogeneic CAR T-cell therapy. The study is assessing the potential of azer-cel to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a highly aggressive type of non-Hodgkin's lymphoma.
• In December 2024, AbbVie (NYSE: ABBV) announced new findings from two ongoing clinical trials assessing epcoritamab, a subcutaneously administered CD3xCD20 bispecific T-cell-engaging antibody, in adult patients with diffuse large B-cell lymphoma (DLBCL) at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.
• In October 2024, ImmunityBio, Inc. (NASDAQ: IBRX), a leader in immunotherapy, announced that the first patients have been dosed in an initial trial evaluating its CAR-NK cell therapy targeting CD-19 for non-Hodgkin's lymphoma (NHL). The QUILT 106 trial is assessing CD19-targeted high-affinity natural killer (t-haNK) cells, first as a monotherapy and later in combination with rituximab after demonstrating safety, in participants with relapsed/refractory CD19+ and CD20+ B-cell NHL. This Phase 1 open-label study aims to enroll up to 10 participants and is being conducted in Johannesburg, Pretoria, and Bloemfontein, South Africa.
• In May 2024, Bristol Myers-Squibb stated that, TRANSCEND FL (NCT04245839) is a global, multicenter, open-label Phase 2 study evaluating the efficacy and safety of Breyanzi in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, including follicular lymphoma. The primary endpoint is the overall response rate, including the best overall response of complete or partial response as assessed by an Independent Review Committee. Secondary endpoints include complete response rate, duration of response, progression-free survival, and safety.
B-Cell Non-Hodgkin Lymphoma Overview
B-Cell Non-Hodgkin Lymphoma (B-Cell NHL) is a type of cancer that originates in the B-lymphocytes, a type of white blood cell crucial to the immune system. B-Cell NHL represents the most common form of Non-Hodgkin Lymphoma, accounting for about 85% of cases. It includes various subtypes, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and mantle cell lymphoma. Symptoms typically include painless swollen lymph nodes, fatigue, fever, night sweats, and unexplained weight loss. Treatments may involve chemotherapy, immunotherapy, targeted therapy, and stem cell transplantation depending on the subtype and disease stage.
Get a Free Sample PDF Report to know more about B-Cell Non-Hodgkin Lymphoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging B-Cell Non-Hodgkin Lymphoma Drugs Under Different Phases of Clinical Development Include:
• VIP 924: Vincerx Pharma
• UBX-303-1: Ubix Therapeutics
• BMF-219: Biomea Fusion Inc.
• SHR-A1912: Shanghai Hengrui Pharmaceutical
• Ociperlimab: BeiGene
• AUTO3: Autolus Limited
• GNC-038: SystImmune Inc
• Poseltinib: Hanmi Pharmaceutical
• Abexinostat: Xynomic Pharmaceuticals
• PF-07901801: Pfizer
• Odronextamab: ZAI Lab
• Zilovertamab: Oncternal Therapeutics
• PF-07901801: Pfizer
• LP-168: Guangzhou Lupeng Pharmaceutical Company LTD.
• TG-1801: TG Therapeutics, Inc.
B-Cell Non-Hodgkin Lymphoma Route of Administration
B-Cell Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
B-Cell Non-Hodgkin Lymphoma Molecule Type
B-Cell Non-Hodgkin Lymphoma Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
B-Cell Non-Hodgkin Lymphoma Pipeline Therapeutics Assessment
• B-Cell Non-Hodgkin Lymphoma Assessment by Product Type
• B-Cell Non-Hodgkin Lymphoma By Stage and Product Type
• B-Cell Non-Hodgkin Lymphoma Assessment by Route of Administration
• B-Cell Non-Hodgkin Lymphoma By Stage and Route of Administration
• B-Cell Non-Hodgkin Lymphoma Assessment by Molecule Type
• B-Cell Non-Hodgkin Lymphoma by Stage and Molecule Type
DelveInsight's B-Cell Non-Hodgkin Lymphoma Report covers around 170+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further B-Cell Non-Hodgkin Lymphoma product details are provided in the report. Download the B-Cell Non-Hodgkin Lymphoma pipeline report to learn more about the emerging B-Cell Non-Hodgkin Lymphoma therapies
https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the B-Cell Non-Hodgkin Lymphoma Therapeutics Market include:
Key companies developing therapies for B-Cell Non-Hodgkin Lymphoma are - Oncternal Therapeutics, Inc, ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, and others.
B-Cell Non-Hodgkin Lymphoma Pipeline Analysis:
The B-Cell Non-Hodgkin Lymphoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of B-Cell Non-Hodgkin Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-Cell Non-Hodgkin Lymphoma Treatment.
• B-Cell Non-Hodgkin Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• B-Cell Non-Hodgkin Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the B-Cell Non-Hodgkin Lymphoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about B-Cell Non-Hodgkin Lymphoma drugs and therapies
https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
B-Cell Non-Hodgkin Lymphoma Pipeline Market Drivers
• Increase in prevalence of B-Cell Non-Hodgkin Lymphoma, launch of several novel therapies for treating B cell Lymphoma are some of the important factors that are fueling the B-Cell Non-Hodgkin Lymphoma Market.
B-Cell Non-Hodgkin Lymphoma Pipeline Market Barriers
• However, high cost of the treatment, side effects associated with the therapies and other factors are creating obstacles in the B-Cell Non-Hodgkin Lymphoma Market growth.
Scope of B-Cell Non-Hodgkin Lymphoma Pipeline Drug Insight
• Coverage: Global
• Key B-Cell Non-Hodgkin Lymphoma Companies: Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Autolus Limited, SystImmune Inc, Hanmi Pharmaceutical, Xynomic Pharmaceuticals, Pfizer, ZAI Lab, Oncternal Therapeutics, Pfizer, Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics, Inc., and others
• Key B-Cell Non-Hodgkin Lymphoma Therapies: VIP 924, UBX-303-1, BMF-219, SHR-A1912, Ociperlimab, AUTO3, GNC-038, Poseltinib, Abexinostat, PF-07901801, Odronextamab, Zilovertamab, PF-07901801, LP-168, TG-1801, and others
• B-Cell Non-Hodgkin Lymphoma Therapeutic Assessment: B-Cell Non-Hodgkin Lymphoma current marketed and B-Cell Non-Hodgkin Lymphoma emerging therapies
• B-Cell Non-Hodgkin Lymphoma Market Dynamics: B-Cell Non-Hodgkin Lymphoma market drivers and B-Cell Non-Hodgkin Lymphoma market barriers
Request for Sample PDF Report for B-Cell Non-Hodgkin Lymphoma Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. B-Cell Non-Hodgkin Lymphoma Report Introduction
2. B-Cell Non-Hodgkin Lymphoma Executive Summary
3. B-Cell Non-Hodgkin Lymphoma Overview
4. B-Cell Non-Hodgkin Lymphoma- Analytical Perspective In-depth Commercial Assessment
5. B-Cell Non-Hodgkin Lymphoma Pipeline Therapeutics
6. B-Cell Non-Hodgkin Lymphoma Late Stage Products (Phase II/III)
7. B-Cell Non-Hodgkin Lymphoma Mid Stage Products (Phase II)
8. B-Cell Non-Hodgkin Lymphoma Early Stage Products (Phase I)
9. B-Cell Non-Hodgkin Lymphoma Preclinical Stage Products
10. B-Cell Non-Hodgkin Lymphoma Therapeutics Assessment
11. B-Cell Non-Hodgkin Lymphoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. B-Cell Non-Hodgkin Lymphoma Key Companies
14. B-Cell Non-Hodgkin Lymphoma Key Products
15. B-Cell Non-Hodgkin Lymphoma Unmet Needs
16 . B-Cell Non-Hodgkin Lymphoma Market Drivers and Barriers
17. B-Cell Non-Hodgkin Lymphoma Future Perspectives and Conclusion
18. B-Cell Non-Hodgkin Lymphoma Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
B-Cell Non-Hodgkin Lymphoma Market https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'B-Cell Non-Hodgkin Lymphoma-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
B-Cell Non-Hodgkin Lymphoma Epidemiology https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'B-Cell Non-Hodgkin Lymphoma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports
• Childhood Atropine For Myopia Progression Market: https://www.delveinsight.com/sample-request/childhood-atropine-for-myopia-progression-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Cardiac Rhythm Management Devices Market: https://www.delveinsight.com/report-store/cardiac-rhythm-management-devices-market
• Tumor Ablation Market: https://www.delveinsight.com/report-store/tumor-ablation-market
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release B-Cell Non-Hodgkin Lymphoma Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Biegene, Oncternal Therapeutics, ZAI Lab, Pfizer, Xynomic Pharma, SystImmune Inc., Autolus Limited, Vincerx Pharma, U here
News-ID: 3995378 • Views: …
More Releases from DelveInsight Business Research

Neuropathic Ocular Pain Pipeline 2025: In-depth Clinical Trials Analysis and Eme …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Neuropathic Ocular Pain pipeline constitutes key companies continuously working towards developing Neuropathic Ocular Pain treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Neuropathic Ocular Pain Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Neuropathic Ocular Pain Market.
The…

Global Functional Electrical Stimulation Devices Market to grow at a CAGR of 8.2 …
According to DelveInsight's analysis, the growing demand for Functional Electrical Stimulation (FES) devices is mainly driven by the rising incidence of musculoskeletal disorders worldwide. Additionally, the increasing focus on pain management therapies and technological advancements in product development are expected to further boost the FES market in the coming years.
DelveInsight's "Functional Electrical Stimulation Devices Market Insights, Competitive Landscape and Market Forecast-2030" report provides the current and forecast market outlook, forthcoming…

Global Intracardiac Echocardiography Devices Market to grow at a CAGR of 5.33% b …
According to DelveInsight's analysis, the demand for intracardiac echocardiography devices is mainly driven by the growing prevalence of arrhythmias, atrial septal defects, and other cardiovascular conditions. Additionally, the increasing number of elderly patients, a rising preference for minimally invasive procedures, the surge in lifestyle-related diseases, and advancements in cardiac-related technologies are all contributing to the overall growth of the intracardiac echocardiography devices market during the forecast period from 2024 to…

Global Anti-Snoring Devices Market to reach USD 2.58 million at a CAGR of 7.02% …
According to DelveInsight's analysis, the Anti-Snoring Device Market is set for significant growth due to the rising prevalence of sleep disorders and associated risk factors like depression, COPD, and obesity. Additionally, an increase in sleep awareness campaigns, as well as the introduction of advanced sleep devices, will drive market expansion from 2024 to 2030.
DelveInsight's "Anti-Snoring Devices Market Insights, Competitive Landscape and Market Forecast-2030" report provides the current and forecast market…
More Releases for Lymphoma
Daratumumab Market Precise Analysis , Forecast || key Players- Multiple Myeloma, …
Looking at the current market trends as well as the promising demand status of the “Daratumumab Market”, it can be projected that the future years will bring out positive outcomes. This research report added by Market Research Hub (MRH) on its online portal delivers clear insight about the changing tendencies across the global market. Readers can gather prime facets connected to the target market which includes product, end-use and application;…
Overview Of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Global Clinical Trials Re …
Researchmoz added Most up-to-date research on "Overview Of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Global Clinical Trials Review, H2, 2017" to its huge collection of research reports.
GlobalData's clinical trial report, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Global Clinical Trials Review, H2, 2017" provides an overview of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) clinical trials scenario. This report provides top line data relating to the clinical trials on Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). Report…
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017 to its growing collection of premium market research reports.
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline landscape.
Hodgkin disease is a cancer of the lymphatic system. It…
Pipeline Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Market Review, H2 2017
"The Report Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline landscape.
Hodgkin disease is a cancer of the lymphatic system. It…
T Cell Lymphoma Market T Cell Lymphoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. T-Cell Lymphoma Market Analysis
2. Mechanism of T-Cell Lymphoma Therapeutics
3. T-Cell Lymphoma Drug Market Overview
3.1 Current Market Scenario
3.2 T Cell Lymphoma Clinical Pipeline Overview
4. T-Cell Lymphoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
5. T-Cell Lymphoma Drug Market Future Prospects
6. T-Cell Lymphoma Drug Clinical Pipeline By Company…
B Cell Lymphoma Market B Cell Lymphoma Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to B Cell Lymphoma
1.1 Outline
1.1.1 Non-Hodgkin’s Lymphoma
1.1.2 Hodgkin’s Lymphoma
1.2 Classification of the B Cell lymphoma
1.2.1 Diffuse Large B Cell Lymphoma
1.2.2 Follicular Lymphoma
1.2.3 Mantle Cell Lymphoma
1.2.4 Burkitt Lymphoma
1.3 Stages of…